vs
Acadia Healthcare Company, Inc.（ACHC）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
Acadia Healthcare Company, Inc.的季度营收约是ROYAL GOLD INC的1.8倍（$829.0M vs $469.1M），ROYAL GOLD INC净利率更高（60.0% vs 0.5%，领先59.5%），ROYAL GOLD INC同比增速更快（142.6% vs 7.5%），过去两年ROYAL GOLD INC的营收复合增速更高（64.2% vs 2.0%）
阿卡迪亚医疗公司是美国的营利性行为医疗健康服务提供商，目前在美国及波多黎各地区运营着超过225家医疗机构，搭建了覆盖广泛的行为健康服务网络，为有相关需求的人群提供专业的心理健康与行为干预服务。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
ACHC vs RGLD — 直观对比
营收规模更大
ACHC
是对方的1.8倍
$469.1M
营收增速更快
RGLD
高出135.0%
7.5%
净利率更高
RGLD
高出59.5%
0.5%
两年增速更快
RGLD
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $829.0M | $469.1M |
| 净利润 | $4.5M | $281.7M |
| 毛利率 | — | — |
| 营业利润率 | — | 63.3% |
| 净利率 | 0.5% | 60.0% |
| 营收同比 | 7.5% | 142.6% |
| 净利润同比 | -50.8% | 147.7% |
| 每股收益（稀释后） | $0.05 | $3.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACHCRGLD
| Q1 26 | $829.0M | $469.1M | ||
| Q4 25 | $821.5M | $375.3M | ||
| Q3 25 | $851.6M | $252.1M | ||
| Q2 25 | $869.2M | $209.6M | ||
| Q1 25 | $770.5M | $193.4M | ||
| Q4 24 | $774.2M | $202.6M | ||
| Q3 24 | $815.6M | $193.8M | ||
| Q2 24 | $796.0M | $174.1M |
净利润ACHCRGLD
| Q1 26 | $4.5M | $281.7M | ||
| Q4 25 | $-1.2B | $93.6M | ||
| Q3 25 | $36.2M | $126.8M | ||
| Q2 25 | $30.1M | $132.3M | ||
| Q1 25 | $8.4M | $113.5M | ||
| Q4 24 | $32.6M | $107.4M | ||
| Q3 24 | $68.1M | $96.2M | ||
| Q2 24 | $78.5M | $81.2M |
毛利率ACHCRGLD
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 73.6% | ||
| Q2 25 | — | 72.6% | ||
| Q1 25 | — | 69.4% | ||
| Q4 24 | — | 70.3% | ||
| Q3 24 | — | 66.6% | ||
| Q2 24 | — | 64.7% |
营业利润率ACHCRGLD
| Q1 26 | — | 63.3% | ||
| Q4 25 | -142.4% | 56.2% | ||
| Q3 25 | 4.7% | 64.4% | ||
| Q2 25 | 5.8% | 67.7% | ||
| Q1 25 | 1.7% | 63.6% | ||
| Q4 24 | 4.9% | 65.9% | ||
| Q3 24 | 12.1% | 61.3% | ||
| Q2 24 | 13.4% | 58.6% |
净利率ACHCRGLD
| Q1 26 | 0.5% | 60.0% | ||
| Q4 25 | -143.3% | 24.9% | ||
| Q3 25 | 4.3% | 50.3% | ||
| Q2 25 | 3.5% | 63.1% | ||
| Q1 25 | 1.1% | 58.7% | ||
| Q4 24 | 4.2% | 53.0% | ||
| Q3 24 | 8.4% | 49.7% | ||
| Q2 24 | 9.9% | 46.6% |
每股收益（稀释后）ACHCRGLD
| Q1 26 | $0.05 | $3.30 | ||
| Q4 25 | $-12.98 | $1.04 | ||
| Q3 25 | $0.40 | $1.92 | ||
| Q2 25 | $0.33 | $2.01 | ||
| Q1 25 | $0.09 | $1.72 | ||
| Q4 24 | $0.36 | $1.63 | ||
| Q3 24 | $0.74 | $1.46 | ||
| Q2 24 | $0.85 | $1.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $158.5M | $234.1M |
| 总债务越低越好 | $2.5B | — |
| 股东权益账面价值 | $2.0B | $7.5B |
| 总资产 | $5.5B | $9.5B |
| 负债/权益比越低杠杆越低 | 1.29× | — |
8季度趋势，按日历期对齐
现金及短期投资ACHCRGLD
| Q1 26 | $158.5M | $234.1M | ||
| Q4 25 | $133.2M | $233.7M | ||
| Q3 25 | $118.7M | $172.8M | ||
| Q2 25 | $131.4M | $248.2M | ||
| Q1 25 | $91.2M | $240.8M | ||
| Q4 24 | $76.3M | $195.5M | ||
| Q3 24 | $82.1M | $127.9M | ||
| Q2 24 | $77.2M | $74.2M |
总债务ACHCRGLD
| Q1 26 | $2.5B | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $1.9B | $0 | ||
| Q2 24 | $1.8B | $50.0M |
股东权益ACHCRGLD
| Q1 26 | $2.0B | $7.5B | ||
| Q4 25 | $1.9B | $7.2B | ||
| Q3 25 | $3.1B | $3.4B | ||
| Q2 25 | $3.1B | $3.3B | ||
| Q1 25 | $3.0B | $3.2B | ||
| Q4 24 | $3.1B | $3.1B | ||
| Q3 24 | $3.0B | $3.0B | ||
| Q2 24 | $3.0B | $3.0B |
总资产ACHCRGLD
| Q1 26 | $5.5B | $9.5B | ||
| Q4 25 | $5.5B | $9.5B | ||
| Q3 25 | $6.4B | $4.5B | ||
| Q2 25 | $6.3B | $3.6B | ||
| Q1 25 | $6.1B | $3.5B | ||
| Q4 24 | $6.0B | $3.4B | ||
| Q3 24 | $5.9B | $3.3B | ||
| Q2 24 | $5.7B | $3.3B |
负债/权益比ACHCRGLD
| Q1 26 | 1.29× | — | ||
| Q4 25 | 1.28× | — | ||
| Q3 25 | 0.74× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.72× | — | ||
| Q4 24 | 0.64× | — | ||
| Q3 24 | 0.62× | 0.00× | ||
| Q2 24 | 0.62× | 0.02× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $61.5M | $293.6M |
| 自由现金流经营现金流 - 资本支出 | — | $278.9M |
| 自由现金流率自由现金流/营收 | — | 59.4% |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 13.78× | 1.04× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ACHCRGLD
| Q1 26 | $61.5M | $293.6M | ||
| Q4 25 | $-86.3M | $241.7M | ||
| Q3 25 | $73.2M | $174.0M | ||
| Q2 25 | $133.5M | $152.8M | ||
| Q1 25 | $11.5M | $136.4M | ||
| Q4 24 | $116.7M | $141.1M | ||
| Q3 24 | $163.1M | $136.7M | ||
| Q2 24 | $171.1M | $113.5M |
自由现金流ACHCRGLD
| Q1 26 | — | $278.9M | ||
| Q4 25 | $-179.5M | — | ||
| Q3 25 | $-63.0M | — | ||
| Q2 25 | $-34.2M | — | ||
| Q1 25 | $-163.2M | — | ||
| Q4 24 | $-86.8M | — | ||
| Q3 24 | $-27.1M | — | ||
| Q2 24 | $16.9M | — |
自由现金流率ACHCRGLD
| Q1 26 | — | 59.4% | ||
| Q4 25 | -21.8% | — | ||
| Q3 25 | -7.4% | — | ||
| Q2 25 | -3.9% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | -11.2% | — | ||
| Q3 24 | -3.3% | — | ||
| Q2 24 | 2.1% | — |
资本支出强度ACHCRGLD
| Q1 26 | — | — | ||
| Q4 25 | 11.3% | — | ||
| Q3 25 | 16.0% | — | ||
| Q2 25 | 19.3% | — | ||
| Q1 25 | 22.7% | — | ||
| Q4 24 | 26.3% | — | ||
| Q3 24 | 23.3% | — | ||
| Q2 24 | 19.4% | — |
现金转化率ACHCRGLD
| Q1 26 | 13.78× | 1.04× | ||
| Q4 25 | — | 2.58× | ||
| Q3 25 | 2.02× | 1.37× | ||
| Q2 25 | 4.43× | 1.15× | ||
| Q1 25 | 1.37× | 1.20× | ||
| Q4 24 | 3.58× | 1.31× | ||
| Q3 24 | 2.39× | 1.42× | ||
| Q2 24 | 2.18× | 1.40× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACHC
| Acute Inpatient Psychiatric Facilities | $471.0M | 57% |
| Other | $140.0M | 17% |
| Specialty Treatment Facilities | $128.0M | 15% |
| Residential Treatment Facilities | $90.0M | 11% |
RGLD
| North America | $258.0M | 55% |
| South and Central America | $110.2M | 23% |
| Europe, Middle East, Africa (EMEA) | $84.8M | 18% |
| Australia Pacific | $16.1M | 3% |
